• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CDC: 05/31/2024: Lab Advisory: Enforcement Discretion Granted for the Use of Conjunctival Swabs with the CDC Human Influenza Virus Real-Time RT-PCR D

Commonground

Senior Moderator
Level: Lab Advisory: Enforcement Discretion Granted for the Use of Conjunctival Swabs with the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A/H5 Subtyping Kit

On May 24, 2024, the U.S. Food and Drug Administration (FDA) granted enforcement discretion for the use of conjunctival swabs as an acceptable specimen type with the CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel, Influenza A/H5 Subtyping Kit.

Laboratories may now submit conjunctival swabs from patients that meet Epidemiologic criteria AND either Clinical OR Public Health Response criteria for novel influenza A virus testing to their state public health laboratories for use with the CDC assay alongside a paired nasopharyngeal swab (NPS). These conjunctival swabs must be collected and transported using the same media as the paired NPS used with the currently cleared CDC kit.

The risk posed by novel influenza A viruses to the public still remains low.

Contact flusupport@cdc.gov for any additional questions, comments, or concerns.

https://www.cdc.gov/locs/2024/05-25...ostic_Panel_Influenza_A_H5_Subtyping_Kit.html
 
Back
Top